Results 11 to 20 of about 1,418,988 (256)

Risk of Bacterial Infection from Proton Pump Inhibitor Use

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017
Currently, proton pump inhibitors are used in a wide range of patients with gastroesophageal reflux disease, peptic ulcer, and upper gastrointestinal symptoms such as dyspepsia.
Sung Soo Kim, Yunju Jo, Seun Ja Park, Jeong Seop Moon, Dong Ho Lee, Jae Jun Kim, Yong Chan Lee, Ethics and Education Committee of Korean College of Helicobacter and Upper Gastrointestinal Research   +7 more
doaj   +2 more sources

Antiplatelet agents and proton pump inhibitors – personalizing treatment

Pharmacogenomics and Personalized Medicine, 2010
Eugene Lin, Rajiv Padmanabhan, Majaz MoonisDepartment of Neurology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USAIntroduction: Antiplatelet therapy remains one of the cornerstones in the ...
Eugene Lin, Rajiv Padmanabhan, Majaz Moonis   +2 more
doaj   +1 more source

Can Impedance-pH Monitoring and High-resolution Manometry Predict Proton Pump Inhibitor Failure in Non-erosive Reflux Disease?

The Korean Journal of Gastroenterology, 2016
Article: Predictors of Proton Pump Inhibitor Failure in Non-erosive Reflux Disease: A Study with Impedance-pH Monitoring and High-resolution Manometry (Neurogastroenterol Motil 2016;28:674-679)
In Du Jeong
doaj   +2 more sources

Proton pump inhibitor-induced nephrotoxicity [PDF]

, 2021
Proton pump inhibitors are widely used, and generally considered safe. In this clinical lesson two cases are presented with a strong suspicion of proton pump inhibitor induced decline of kidney function.
Dekker, F W, Klatte, D C F, Gansevoort, R T, Wiegersma, J S   +3 more
core   +4 more sources

Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. [PDF]

, 2012
Introduction Emerging epidemiological evidence suggests that proton pump inhibitor (PPI) acid-suppression therapy is associated with an increased risk of Clostridium difficile infection (CDI).
Sutton, AJ, Imad M. Tleyjeh (104252), Tannir Mohamad Al, Alex J Sutton, AlGhamdi, M, Muhammad Riaz (104236), Bin Abdulhak, AA, Ibrahim Talal, Mushabab AlGhamdi (112556), Baddour, LM, Alasmari Faisal A., A. A. Bin Abdulhak (7656569), Abed Allehibi, Talal Ibrahim (112568), Allehibi, A., Alasmari, FA, Faisal A. Alasmari (112549), F. A. Alasmari (7656575), A. R. Khan (3951662), AlGhamdi Mushabab, A. AlLehibi (7656593), Khan, AR, Al Tannir, M, Tleyjeh, IM, I. M. Tleyjeh (7656566), AlGhamdi, M., Abed AlLehibi (112573), Khan, A. R., Alex J. Sutton (112577), Garbati Musa A., L. M. Baddour (7656596), Aref A Bin Abdulhak, M. A. Garbati (7656578), M. Al Tannir (7656584), Bin Abdulhak, A. A., M. AlGhamdi (7656581), Erwin, P. J., Imad M Tleyjeh, Khan Abdur Rahman, Tleyjeh, I. M., Patricia J Erwin, T. Ibrahim (7656590), Muhammad Riaz, Abdur Rahman Khan (104234), Garbati, MA, Allehibi, A, Bin Abdulhak Aref A., Erwin, PJ, Sutton Alex J., M. Riaz (7656572), Riaz Muhammad, Musa A Garbati, Alasmari, F. A., Patricia J. Erwin (104246), Talal Ibrahim, Abdur Rahman Khan, Ibrahim, T., Mushabab AlGhamdi, A. J. Sutton (7648487), Faisal A Alasmari, Ibrahim, T, Mohamad Al Tannir (112562), Mohamad Al Tannir, Erwin Patricia J., Larry M Baddour, Baddour Larry M., Al Tannir, M., P. J. Erwin (7656587), Aref A. Bin Abdulhak (104239), Garbati, M. A., Larry M. Baddour (104249), Riaz, Muhammad, Riaz, M, Tleyjeh Imad M., Baddour, L. M., Sutton, A. J., Musa A. Garbati (104244), AlLehibi Abed   +77 more
core   +1 more source

Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors

eJHaem, 2020
Background Iron deficiency anemia without evidence for blood loss can present a diagnostic challenge. Proton pump inhibitors have been associated with iron deficiency anemia for many years, yet the relationship between the two until recently was not ...
Michael Boxer
doaj   +1 more source

Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy

BMC Gastroenterology, 2012
Background High dose intravenous proton pump inhibitor after endoscopic therapy for peptic ulcer bleeding has been recommended as adjuvant therapy.
Yen Hsu-Heng, Yang Chia-Wei, Su Wei-Wen, Soon Maw-Soan, Wu Shun-Sheng, Lin Hwai-Jeng   +5 more
doaj   +1 more source

Prescribing trends of proton pump inhibitors, antipsychotics and benzodiazepines of medicare part d providers

BMC Geriatrics, 2022
Background Proton pump inhibitors, benzodiazepines, and antipsychotics are considered potentially inappropriate medications in older adults according to the American Geriatric Society Beers Criteria, and deprescribing algorithms have been developed to ...
Jennifer M. Toth, Saumil Jadhav, Holly M. Holmes, Manvi Sharma   +3 more
doaj   +1 more source

Determinants of proton pump inhibitor prescription behavior: a systematic scoping review protocol

, 2022
A systematic scoping literature review to identify determinants of proton pump inhibitor prescription ...
Laurens van Gestel, Sara Mensink-Bout, Gertrude van den Brink, Marieke Adriaanse, Jessica C. Kiefte-de Jong   +4 more
core   +1 more source

Proton pump inhibitor-induced Sweet’s syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer

Dermatology Practical & Conceptual, 2015
Background: Sweet’s syndrome, also referred to as acute febrile neutrophilic dermatosis, can either occur as an idiopathic disorder or associated with another condition, including cancer, or induced by exposure to a drug.
Philip R. Cohen
doaj   +1 more source